Terms: = Thyroid cancer AND ITK, PSCTK2, 3702, Q08881, ENSG00000113263, EMT, MGC126258, LYK, MGC126257 AND Treatment
176 results:
1. Biological functions of LncRNA SNHG14 in the development of thyroid cancer cells via targeting miR-206.
Sang Y; Min R; Huang T; Zhang J
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):77-84. PubMed ID: 38678623
[TBL] [Abstract] [Full Text] [Related]
2. CD73 mitigates ZEB1 expression in papillary thyroid carcinoma.
Vedovatto S; Oliveira FD; Pereira LC; Scheffel TB; Beckenkamp LR; Bertoni APS; Wink MR; Lenz G
Cell Commun Signal; 2024 Feb; 22(1):145. PubMed ID: 38388432
[TBL] [Abstract] [Full Text] [Related]
3. Characterization of a germline variant TNS1 c.2999-1G > C in a hereditary cancer syndrome family.
Di X; Wang D; Wu J; Zhu X; Wang Y; Yan J; Wen L; Jiang H; Wen D; Shu B; Zhang S
Gene; 2024 May; 908():148304. PubMed ID: 38387708
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of the Therapeutic Effects of Harmine on Anaplastic thyroid cancer Cells.
Baldini E; Cardarelli S; Campese AF; Lori E; Fallahi P; Virili C; Forte F; Pironi D; Di Matteo FM; Palumbo P; Costanzo ML; D'Andrea V; Centanni M; Sorrenti S; Antonelli A; Ulisse S
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256193
[TBL] [Abstract] [Full Text] [Related]
5. AEBP1 promotes papillary thyroid cancer progression by activating BMP4 signaling.
Ju G; Xing T; Xu M; Zhang X; Sun Y; Mu Z; Sun D; Miao S; Li L; Liang J; Lin Y
Neoplasia; 2024 Mar; 49():100972. PubMed ID: 38237535
[TBL] [Abstract] [Full Text] [Related]
6. CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway.
Chen X; Shen H; Liu H; Tan L; Zhang N
Funct Integr Genomics; 2024 Jan; 24(1):10. PubMed ID: 38221563
[TBL] [Abstract] [Full Text] [Related]
7. Exploration and validation of key genes associated with early lymph node metastasis in thyroid carcinoma using weighted gene co-expression network analysis and machine learning.
Liu Y; Yin Z; Wang Y; Chen H
Front Endocrinol (Lausanne); 2023; 14():1247709. PubMed ID: 38144565
[TBL] [Abstract] [Full Text] [Related]
8. Phosphorylation of AHR by PLK1 promotes metastasis of LUAD via DIO2-TH signaling.
Li C; Allison DB; He D; Mao F; Wang X; Rychahou P; Imam IA; Kong Y; Zhang Q; Zhang Y; Liu J; Wang R; Rao X; Wu S; Evers BM; Shao Q; Wang C; Li Z; Liu X
PLoS Genet; 2023 Nov; 19(11):e1011017. PubMed ID: 37988371
[TBL] [Abstract] [Full Text] [Related]
9. USP10 suppresses ABCG2-induced malignant characteristics of doxorubicin-resistant thyroid cancer by inhibiting PI3K/AKT pathway.
Sun J; Xiang Q; Ding D; Yan N
J Bioenerg Biomembr; 2023 Dec; 55(6):457-466. PubMed ID: 37919637
[TBL] [Abstract] [Full Text] [Related]
10. Network Pharmacological Analysis and Experimental Validation of the Effects of Silybin on Proliferation, Migration, and Immunotherapy of Papillary thyroid cancer.
Xie W; Li H; Lin Q; Ke N
Endocr Metab Immune Disord Drug Targets; 2024; 24(6):672-690. PubMed ID: 37855349
[TBL] [Abstract] [Full Text] [Related]
11. TRIP6 disrupts tight junctions to promote metastasis and drug resistance and is a therapeutic target in colorectal cancer.
Gou H; Wong CC; Chen H; Shang H; Su H; Zhai J; Liu W; Liu W; Sun D; Wang X; Yu J
Cancer Lett; 2023 Dec; 578():216438. PubMed ID: 37827326
[TBL] [Abstract] [Full Text] [Related]
12. Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for cancer treatment - Pharmacology and Mechanisms.
Xing Z; Su A; Mi L; Zhang Y; He T; Qiu Y; Wei T; Li Z; Zhu J; Wu W
Drug Des Devel Ther; 2023; 17():2909-2929. PubMed ID: 37753228
[TBL] [Abstract] [Full Text] [Related]
13. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing emt, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract] [Full Text] [Related]
14. Hypoxic papillary thyroid carcinoma cells-secreted exosomes deliver miR-221-3p to normoxic tumor cells to elicit a pro-tumoral effect by regulating the ZFAND5.
Yu F; Deng X; Zhong Y; Guo B; Zhang X; Wu B
Exp Cell Res; 2023 Oct; 431(1):113716. PubMed ID: 37488006
[TBL] [Abstract] [Full Text] [Related]
15. CCND1-associated ceRNA network reveal the critical pathway of TPRG1-AS1-hsa-miR-363-3p-MYO1B as a prognostic marker for head and neck squamous cell carcinoma.
Li Z; Qiu X; He Q; Fu X; Ji F; Tian X
Sci Rep; 2023 Jul; 13(1):11831. PubMed ID: 37481637
[TBL] [Abstract] [Full Text] [Related]
16. Unraveling the Roles of miR-204-5p and HMGA2 in Papillary thyroid cancer Tumorigenesis.
Van Branteghem C; Augenlicht A; Demetter P; Craciun L; Maenhaut C
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445942
[TBL] [Abstract] [Full Text] [Related]
17. A specific RAGE-binding peptide inhibits triple negative breast cancer growth through blocking of Erk1/2/NF-κB pathway.
Dai X; Hou Y; Deng T; Lin G; Cao Y; Yu G; Wei W; Zheng Q; Huang L; Ma S
Eur J Pharmacol; 2023 Sep; 954():175861. PubMed ID: 37380046
[TBL] [Abstract] [Full Text] [Related]
18. p18INK4C and BRCA1 inhibit follicular cell proliferation and dedifferentiation in thyroid cancer.
Bai F; Liu X; Zhang X; Mao Z; Wen H; Ma J; Pei XH
Cell Cycle; 2023 Jul; 22(13):1637-1653. PubMed ID: 37345432
[TBL] [Abstract] [Full Text] [Related]
19. Circ_0003747 promotes thyroid cancer progression by sponging miR-338-3p to upregulate PLCD3 expression.
Dou XL; Xia FD; Li XY
Epigenetics; 2023 Dec; 18(1):2210339. PubMed ID: 37166441
[TBL] [Abstract] [Full Text] [Related]
20. TESC promotes differentiated thyroid cancer development by activating ERK and weakening NIS and radioiodine uptake.
Guo Y; Cai Y; Song F; Zhu L; Hu Y; Liu Y; Ma W; Ge J; Zeng Q; Ding L; Li L; Zheng G; Ge M
Endocrine; 2023 Sep; 81(3):503-512. PubMed ID: 37020077
[TBL] [Abstract] [Full Text] [Related]
[Next]
